Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

BACKGROUND: The efficacy and safety of rituximab-based chemotherapy (R-chemo), the standard regimen for patients with diffuse large B-cell lymphoma (DLBCL), which is more common in Asia than in Western countries, are well confirmed in randomized controlled trials (RCTs). However, the safety and effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jianqiu, Song, Yongping, Su, Liping, Xu, Li, Chen, Tingchao, Zhao, Zhiyun, Zhang, Mingzhi, Li, Wei, Hu, Yu, Zhang, Xiaohong, Gao, Yuhuan, Niu, Zuoxing, Feng, Ru, Wang, Wei, Peng, Jiewen, Li, Xiaolin, Ouyang, Xuenong, Wu, Changping, Zhang, Weijing, Zeng, Yun, Xiao, Zhen, Liang, Yingmin, Zhuang, Yongzhi, Wang, Jishi, Sun, Zimin, Bai, Hai, Cui, Tongjian, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962436/
https://www.ncbi.nlm.nih.gov/pubmed/27460571
http://dx.doi.org/10.1186/s12885-016-2523-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962436/
https://www.ncbi.nlm.nih.gov/pubmed/27460571
http://dx.doi.org/10.1186/s12885-016-2523-7

Ejemplares similares